Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

PathY5 > Myeloma and MGUS > Flashcards

Myeloma and MGUS Flashcards

1
Q

What are the key features of myeloma?

A

Monoclonal PCs
Paraprotein

(B) Osteolytic lesions (bone destruction)
(A) Anaemia
(R) Kidney failure

Infections/ immunosuppression
Angiogenesis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What does CRAN mean?

A

Calcaemia (hyper) >2.75

Renal failure Cr >177, eGFR<40

Anaemia Hb <100

N Bone pain 1+ lytic lesion

Multiple myeloma has very characteristic complications that arise from complex interactions with the tumour microenvironment (bone disease) or large-scale Ig secretion (renal failure)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What type of cells are in multiple myeloma?

A

Mature B cells which can make Ig

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

How is multiple myeloma linked to MGUS?

A

Transformation results from a range of numeric and structural genetic aberrations that accumulate from a pre-malignant condition (“MGUS”) to terminal progression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is the second most common haematopoietic malignancy?

A

Multiple myeloma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is the survival of multiple Myeloma?

A

4-7 years

Novel treatment approaches combined with “old-fashioned” chemotherapy are increasing survival rates

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

How do B cells mature?

A
  1. B cell encounters antigen and goes into germinal centre
  2. Affinity maturation: Somatic hypermutation and antigen selection
  3. Class switching to get correct isotype
  4. Plasmablast goes to bone marrow to produce antibodies
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Where can mutations occur?

A

> Switching off cellular characteristics that are no longer required, such as cell cycling

> Activating programmes that are essential for antibody production

> Undergoing apoptosis if they do not find a receptive niche in the bone marrow

Failure to complete these programmes correctly could potentially leave active cellular processes, which may result in the features of myeloma.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are key transcription factors in myeloma?

A

BCL-6, B cell lymphoma 6
BLIMP1, B lymphocyte-induced maturation protein 1

CIITA, MHC class II transactivator
ID3, DNA-binding protein inhibitor ID3
PAX5, paired box gene 5
XBP1, X box-binding protein 1.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Which cell secretes the most proteins?

A

Plasma Cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is the pathogenesis of multiple myeloma?

A

Insult to cell (infection/ inflammation)

MGUS

Microenvironment changes

Oncogenes and genetic changes etc.

Myeloma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is the progression to Myeloma?

A
  1. MGUS (No CRAB)
  2. Smouldering Myeloma (No CRAB)
  3. Multiple Myeloma (CRAB)
  4. B Cell leukaemia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What would be seen in blood of MGUS?

A

Monoclonal serum protein < 30g/L

BM plasma cells < 10%

Annual risk of progression to MM 1-2%

Rare in young, increasing incidence with ag

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What would be seen in blood of smouldering myeloma?

A

Monoclonal serum protein ≥ 30g/L

BM plasma cells ≥ 10%

Annual risk of progression to MM 10%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is the epidemiology of myeloma?

A

o 4,500 new cases per year in the UK

o 15-20,000 people are living with myeloma in the UK [Incidence 5/100,000 per year]

o 15% of blood cancers and 1% of cancers

o 2x more frequent in blacks than in whites, less common in Asians

o Median age at diagnosis 65-70y -> median survival 3-4y (6-10y in patients fit for intensive treatment)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What investigations do you do for myeloma?

A 
Electrophoresis
Blood film
Urine
ESR
BM aspirate
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What would you find when investigating myeloma?

A 
Electrophoresis: Dense ban of IgG/IgA monoclonal proteins
Blood film: Rouleaux
Urine: Bence Jones proteins
ESR: High
BM aspirate: >10% plasma cells
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What is the aetiology of multiple myeloma?

A

Unsure

Chronic infection/ inflammation: RhA/ HHV8/ HIV - more chance for multiplication errors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What staging system is used for multiple myeloma?

A

Durie-Salmon staging system

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Which mutations are linked to MGUS?

A

t(14q32) = 50%

del (Chr13) = 50%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Which mutations are linked to MM?

A

N-RAS, K-RAS = 30%

p16 methylation = 40%

2nd translocations = …

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

How can diagnostics be used in MGUS and MM?

A

Serum protein electrophoresis: Monoclonal gammopathy

Bone Marrow Aspirates: Large Golgi and ER (Immature cells = poor prognosis)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What is the difference between mature and immature cells?

A

o Mature plasmocytic myeloma cells = clumped chromatin, abundant cytoplasm, rare nucleoli

o Immature plasmoblastic myeloma cells = prominent nucleoli, reticular chromatin, less abundant cytoplasm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

What would be positive/ negative in immunophenotyping?

A 
o Positive:
CD38
CD138
CD56/58
Monotypic cytoplasmic Ig
Light Chain restriction (Kappa or Lambda positive)

o Negative:
CD19
CD20 (hence, Rituximab (targets CD20) cannot be used for B-cell depletion therapy)
Surface Ig

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Summarise treatment in MM

A

o (1) “Classical” cytostatic drugs = melphalan (alkylating agents)

o (2) Proteasome inhibitors

o (3) “IMIDs” / Immunomodulatory Drugs = thalidomide, lenalidomide, pomalidomide

o (4) MoAbs / Monoclonal Antibodies = daratumumab

o Steroids

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

What do alkylating agents do?

A

o Adds alkyl ground to DNA -> crosslinks and blocks DNA replication -> lymphopenia

o Related compounds = cyclophosphamide, chlorambucil, ifosphamide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

What is an autologous stem cell transplant?

A

§ (1) stem cells collected from blood and stored

§ (2) high dose melphalan used to kill myeloma cells

§ (3) re-infusion of stem cells to rescue blood formation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

What do proteasome inhibitors do?

A

Causes proteins misfolded in ER to accumulate as proteasome cannot destroy them.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

What is a proteasome?

A

Proteasome = large enzyme complex that degrades most intracellular proteins (i.e. damaged proteins) by ubiquinating (adding a functional group) and marking the protein for degradation

Prevents cell death by accumulation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Why is thalidomide good?

A

Targets the turnover of transcription factors that are particularly important for myeloma cell survival

(Previously used as an anti-morning sickness drug which was found to be teratogenic)

31
Q

Why are MoAbs good?

A

I.E. Daratumumab

o Binds CD38, which then leads to cell death through different processes:

§ Initiates complement cascade (through C1q activation) and formation of MAC -> cell death

§ Binds to CTL and eventual cell death

§ Binds macrophages and eventual cell engulfment and death

§ Direct cellular apoptosis (autologous) through crosslinking

32
Q
  1. Which of the following is NOT a typical clinical myeloma characteristic?
    a. Anaemia
    b. Lytic bone disease
    c. Splenomegaly
    d. Renal impairment
A

c. Splenomegaly

33
Q

Which of the following IS a key histopathological myeloma marker?

a. CD19
b. CD38 / CD138
c. Surface Ig
d. CD20

A

b. CD38 / CD138

34
Q

Myeloma cells have a very well developed and extensive …

a. Nucleus
b. Mitochondrial mass
c. ER
d. Cell membrane

A

c. ER

35
Q

How do we detect myeloma bone disease?

A

MRI:
High sensitivity for marrow infiltration
Response monitoring possible
Expensive & limited availability

CT:
Detects very small lesions
Good for radiotherapy planning
Higher radiation dose

PET:

Detects active disease
High costs, limited availability

36
Q

What is myeloma nephropathy?

A

FLCs activate inflammatory mediators in the proximal tubule epithelium

Fanconi syndrome (renal tubule acidosis) with FLC crystal deposition.

Proximal tubule necrosis

Cast nephropathy

37
Q

What is the epidemiology of Myeloma?

A

‘Black male in his 60’s’

  • Median age 67 years
  • Incidence increases with age
  • Only 1% of patients are younger than 40 years
  • Men > women
  • Black > Caucasian and Asians
  • > 17,600 people with myeloma live today in the UK
  • Prevalence of myeloma in the community is increasing
38
Q

What is the aetiology of myeloma?

A

Aetiology is unknown but, myeloma is always preceded by a premalignant condition:
Monoclonal Gammopathy of Uncertain Significance (MGUS)

Risk factors
• Obesity increases the risk for myeloma
• Age
• Genetics
• Incidence in black population
• Sporadic cases of familiar myeloma
39
Q

What is the epidemiology of MGUS?

A
  • the most common (known) premalignant condition
  • incidence increases with age
  • up to 1% - 3.5% in elderly population
  • average risk for progression : 1% annually
  • IgG or IgA MGUS → myeloma
  • IgM → lymphoma
40
Q

What are the risk factors for MGUS?

A

Risk factors
• Non-IgG M-spike
• M-spike >15g/L
• Abnormal serum free light chain (FLC) ratio

41
Q

What is smouldering myeloma?

A

2 criteria:

  1. Serum monoclonal protein (IgG or IgA)>30g/l
  2. Absence of myeloma defining event and amyloidosis
  • Low, intermediate risk: observation
  • High risk (≥2 factors): ? treatment
42
Q

What are primary events in MM?

A

• Hyperdiploidy (60%)
- additional odd number Chr

• IGH rearrangements (Chr 14q32)

  • t(11;14) IGH/CCND1
  • t(4;14) IGH/FGFR3
  • t(14;16) IGH/MAF
43
Q

What are secondary events in MM?

A
  • KRAS, NRAS
  • t(8;14) IGH/MYC
  • 1q gain / 1p del
  • del 17p (TP53)
  • 13- / del 13q
44
Q

How does MM occur?

A

Clonal advantage - competition selection for BM niche - migration and founder effect

45
Q

What is the clinical presentation of bone disease - 80% of pts?

A
  • Proximal skeleton
  • Back (spine), chest wall and pelvic pain
  • Osteolytic lesions, never osteoblastic
  • Osteopenia
  • Pathological fractures
  • Hypercalcaemia
46
Q

How is imaging used in MM?

A

• Plain XR films (skeletal surveys): are now obsolete
– Low sensitivity, require >30% bone mass loss

  • Whole body CT scan low-dose
  • CT / FDG-PET scan
  • Whole-body diffusion-weighted MRI
  • Bone marrow cellularity
  • Active vs treated disease
47
Q

What are emergencies in myeloma?

A

Cord compression

Hypercalcaemia (• Presents with drowsiness, constipation, fatigue, muscle weakness, AKI
• Fluids, steroids, zolendronic acid)

48
Q

What is myeloma kidney disease and what is cast nephropathy?

A

– Serum creatinine >177μmol/L (>2mg/dL ) or eGFR <40ml/min (CDK-EPI)
– Acute kidney injury and result of myeloma

Cause of myeloma kidney disease:
❑ Cast nephropathy is caused by high serum free light chains (FLC) levels and Bence Jone proteinuria

❑ Hypercalcaemia, loop diuretics, infection,
dehydration, nephrotoxics
• 20-50% acute kidney injury at diagnosis
• 2-4% of newly diagnosed patients will require dialysis
• 25% develop renal insufficiency at relapse

49
Q

How does kidney disease determine prognosis?

A

Early mortality in severe kidney disease is an area on unmet clinical need
• 12% early death (<2 months)
• Prolonged hospital stay, lethal infections
• Nephrotoxic or renal excreted myeloma drugs: eg zoledronic acid, lenalidomide

Myeloma kidney disease should be treated as an emergency

50
Q

Why do infections happen in myeloma?

A
  • Immunoparesis: low serum normal Igs
  • Myeloid, T cells and NK cells impairment
  • Chemotherapy impairs immune response
  • Myeloma immune evasion
51
Q

What is in a myeloma diagnostic workup?

A

Immunoglobulin studies
• Serum protein electrophoresis
• Serum free light chain levels
• 24h Bence Jones protein

Bone marrow aspirate
and biopsy
• IHC for CD138

FISH analysis
• Should include at least
high risk abnormalities

Flow cytometry immunophenotyping
• Diagnosis
• MRD

52
Q

How is myeloma linked to AL amyloidosis?

A

MGUS or myeloma in the background

Misfolded free light chains aggregate into amyloid
fibrils in target organs

The amyloidogenic potential of light chains is more
important than their amount

Amyloid fibrils stain with Congo Red, are solid, nonbranching and randomly arranged with a diameter of
7 – 12 nm

Lambda light chain is involved in 60%

  • IGLV6-57 in kidney
  • IGLV1-44 in cardiac
53
Q

What does AL amyloidosis do?

A

Common target organs: kidney, heart, liver, neuropathy

Clinical presentation:
• Nephrotic syndrome (70%)
– Proteinuria (not BJP!), peripheral oedema
• Unexplained heart failure → determinant of prognosis
– Raised NT-proBNP
– Abnormal echocardiography and cardiac MRI
• Sensory neuropathy
• Abnormal liver function tests
• Macroglossia

54
Q

What is MGRS?

A

“…MGRS applies specifically to any B-cell clonal lymphoproliferation where there are:

1. one or more kidney lesions caused by mechanisms related to the produced
monoclonal immunoglobulin (Ig) and
  1. the underlying B cell clone does not cause tumor complications or meet current
    hematological criteria for immediate specific therapy”
55
Q

What is the pathology of MGRS?

A 
• Rare disease, several subtypes
• Demonstration of the involved
monoclonal Ig or light chain is
possible in most cases
• Work up similar to myeloma
• Many patients will require
myeloma-type treatment aiming
to renal survival
56
Q

What is myeloma therapy?

A 
Alkylators and steroids
Thalidomide
IMiD or Cereblon Binding Molecules
Proteasome inhibitors
moAbs
Daratumumab
57
Q

How can thalidomide be used in MM?

A

• Thalidomide in combination with cyclophosphamide and dexamethasone was established in the
treatment of relapsed myeloma
• It was later replaced older therapies as a front line treatment prior to autologous SCT

58
Q

What is IMiD?

A 
Thalidomide lead the way for the development of a new class of anti-myeloma drugs
Immunomodulatory drugs (IMiD)
  • Lenalidomide - 2005: more potent, different toxicity profile, better tolerated
  • Pomalidomide – 2013 : even more potent than Lenalidomide
  • Iberdomide – awaits approval
59
Q

How are proteasome inhibitors used in MM?

A

Myeloma cells are protein production factories
Proteasome is crucial in removing misfolded protein
Accumulation of misfolded protein → endoplasmic reticulum
stress and unfolded protein response → apoptosis Alteration of NF-κB pathway

60
Q

Which moabs can be used?

A

anti-CD38: Daratumumab and Isatuximab

Daratumumab is the first therapeutic moAb approved for multiple myeloma (2015)
• CD38 is strongly expressed in
normal and malignant plasma cells
• Not a lineage specific marker

61
Q

What is the treatment algorithm for MM?

A

See picture notes

62
Q

What are emerging treatments in MM?

A

Belantamab mafodotin
Anti-BCMA toxin conjugate
30% response rate in refractory myeloma

anti-myeloma activity of CAR-BCMA T cells
BCMA

BiTE in myeloma
CD3-BCMA and CD3-FcRL5
BiTE under development
The different types of bispecific antibodies

63
Q

Which immunoglobulins are linked to MM?

A

IgA and IgG

Excess of monoclonal light chains in serum (kappa or lambda)

64
Q

What does MGUS cause?

A

higher incidence of osteoporosis, thrombosis and

bacterial infection compared to general population

65
Q

What is the clinical spectrum of myeloma?

A 
MGUS
Smouldering myeloma
Symptomatic myeloma
Remitting relapsing disease
Refractory
Plasma cell leukaemia

(see picture notes)

66
Q

How do you manage cord compression?

A
  • Diagnosis & treatment within 24hrs
  • MRI scan
  • Ig and FLC studies +/- biopsy
  • Dexamethasone
  • Radiotherapy
  • Neurosurgery: rarely required
  • Stabilise unstable spine
  • MDT meeting
67
Q

How are alkylators and steroids used?

A

Melphalan
• Nitrogen mustard derivate, in use since the 1960’s
• Backbone of myeloma therapy until late 1990’s
• High-dose melphalan 200mg/m2
still in use in Autologous SCT

Cyclophosphamide
• Widely used in combination with steroids and/or other drugs
• Immunomodulation and microenvironment

Dexamethasone and Prednisolone
• Induce apoptosis in myeloma cells
• Strong synergy, part of almost all combination regimens

68
Q

Which proteasome inhibitors are used in myeloma?

A

Bortezomib – 2003
• Currently approved for first line or relapse
• iv or s/c use
• Neuropathy is main toxicity

Carfilzomib - 2012
• More potent than Bortezomib
• Approved in relapse
• iv only
• thrombocytopenia, cardiotoxicity

Ixazomib - 2015
• Approved in relapse, in combination
• Oral drug
• Favourable toxicity profile

69
Q

What is anti-myeloma activity of CAR-BCMA T cells

BCMA?

A 
B cell maturing antigen, specific for plasma
cells (normal and malignant)
➢6 patients with refractory disease and
extensive BM infiltration were treated
➢1 patient obtained a very good partial
remission
➢1 patients achieved stringent CR
(undetectable disease)
70
Q

What is the most common cytogenetic abnormality in myeloma?

A

Hyperdiploid karyotype

71
Q 
Which of these is not a typical myeloma characteristic:
Anaemia
Lytic bone disease
Splenomegaly
Renal impairment
A

Splenomegaly

72
Q

How does excess free light chains cause cast nephropathy

A

Proximal tubule take up light chains and put them back in circulation

At some point when overwhelmed they are stressed and undergo inflammation and fibrosis and re modelling

They form material within tubules (Casts) and this with inflammation leads to kidney injury

73
Q

What diseases may you get in MM?

A

Chest infections
Fungal infections (in later stages)
Viral infections - Herpes zoster

74
Q

What is the key histopathological myeloma marker?

A

CD138

PathY5 (98 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions